KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy ... and a CE mark, according to ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

Srinivas Sadda, MD In a “viewpoint” published in JAMA Ophthalmology in late January, Srinivas Sadda, MD, a retina specialist ... that can lead to geographic atrophy and eventually blindness.

"The approval of SYFOVRE marks a significant milestone for GA patients across ... 1 It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells ...

for adult patients suffering from geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first approved treatment for GA in Australia, offering hope to over ...

"The approval of SYFOVRE marks a significant milestone for GA patients ... caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by ...

"The approval of SYFOVRE marks a significant milestone for GA patients ... caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Piper Sandler reaffirmed its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00. The firm's analysis was based on a recent survey of ophthalmologists ...

While two treatments have recently been approved for late-stage dry AMD, also known as geographic atrophy (GA), there ... and preservation of retinal function, among other benefits.

Securities reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a stable price target of $30.00, following the company's announcement of its first ex-US approval for Syfovre in ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ... 1 "The approval of SYFOVRE marks a significant milestone for GA patients ...